| Literature DB >> 35914746 |
Hyung Seok Park1, Jeea Lee2, Jee Ye Kim3, Jung Mi Park4, Yonghan Kwon4.
Abstract
PURPOSE: Advanced energy devices, including electrosurgical bipolar systems or ultrasonic shears, are widely used in various surgeries. An electrosurgical bipolar device allows surgeons to grasp and dissect tissues, as well as simultaneously ligate and cut vessels and lymphatics during surgery. This study aimed to evaluate the effects of advanced bipolar energy devices on the reduction in seroma formation during mastectomy, axillary staging, and/or reconstruction.Entities:
Keywords: Breast Neoplasms; Postoperative Complications; Seroma; Surgical Procedures, Operative
Year: 2022 PMID: 35914746 PMCID: PMC9411027 DOI: 10.4048/jbc.2022.25.e29
Source DB: PubMed Journal: J Breast Cancer ISSN: 1738-6756 Impact factor: 2.922
Figure 1Study diagram according to the CONSORT statement.
Clinicopathologic characteristics of the study population
| Variables | Control (n = 41) | Ligasure (n = 41) | ||
|---|---|---|---|---|
| Age (yr) | 52.46 ± 12.95 | 50.15 ± 13.90 | 0.44† | |
| BMI (kg/m2) | 23.44 ± 3.84 | 23.59 ± 4.03 | 0.86† | |
| Menopause | 0.17 | |||
| Pre-menopause | 22 (53.7) | 28 (68.3) | ||
| Post-menopause | 19 (46.3) | 13 (31.7) | ||
| Comorbidity | 0.82 | |||
| Yes | 15 (36.6) | 13 (31.7) | ||
| No | 26 (63.4) | 28 (68.3) | ||
| Laterality | 0.66 | |||
| Left | 23 (56.1) | 20 (48.8) | ||
| Right | 18 (43.9) | 21 (51.2) | ||
| Operation | 0.41 | |||
| PM+ALND | 18 (43.9) | 17 (41.5) | ||
| MRM | 9 (22.0) | 14 (34.1) | ||
| TM+Reconstruction | 14 (34.1) | 10 (24.4) | ||
| Reconstruction | 0.61 | |||
| No | 27 (65.9) | 31 (75.6) | ||
| Tissue expander | 13 (31.7) | 9 (22.0) | ||
| Direct-to-implant | 1 (2.4) | 1 (2.4) | ||
| T | 0.48 | |||
| ≤ T1 | 26 (63.4) | 29 (70.7) | ||
| > T1 | 15 (36.6) | 12 (29.3) | ||
| N | 0.50 | |||
| N0 | 19 (46.3) | 16 (39.0) | ||
| N1–N3 | 22 (53.7) | 25 (61.0) | ||
| M | > 0.99 | |||
| M0 | 41 (50.6) | 40 (49.4) | ||
| M1 | 0 (0.0) | 1 (2.4) | ||
| TNM stage | 0.43 | |||
| 0 | 3 (7.3) | 2 (4.9) | ||
| I | 13 (31.7) | 14 (34.1) | ||
| II | 19 (46.3) | 13 (31.7) | ||
| III | 6 (14.6) | 11 (26.8) | ||
| IV | 0 (0.0) | 1 (2.4) | ||
| Histologic grade | 0.94 | |||
| Grade I | 9 (22.0) | 10 (24.4) | ||
| Grade II | 24 (58.5) | 23 (56.1) | ||
| Grade III | 8 (19.5) | 7 (17.1) | ||
| Unknown | 0 (0.0) | 1 (2.4) | ||
| ER | 0.79 | |||
| Positive | 32 (78.0) | 33 (80.5) | ||
| Negative | 9 (22.0) | 8 (19.5) | ||
| PR | 0.82 | |||
| Positive | 24 (58.5) | 25 (61.0) | ||
| Negative | 17 (41.5) | 16 (39.0) | ||
| HER2 | 0.78 | |||
| Positive | 8 (19.5) | 7 (17.1) | ||
| Negative | 33 (80.5) | 34 (82.9) | ||
| Radiotherapy‡ | 0.30 | |||
| Yes | 26 (65.0) | 31 (75.6) | ||
| No | 14 (35.0) | 10 (24.4) | ||
| Chemotherapy‡ | 0.25 | |||
| Yes | 9 (22.5) | 14 (34.1) | ||
| No | 31 (77.5) | 27 (65.9) | ||
| Target therapy‡ | 0.34 | |||
| Yes | 8 (20.0) | 5 (12.2) | ||
| No | 32 (80.0) | 36 (87.8) | ||
| Hormone therapy‡ | 0.40 | |||
| Yes | 29 (72.5) | 33 (80.5) | ||
| No | 11 (27.5) | 8 (19.5) | ||
| Recurrence‡ | - | |||
| Yes | 0 (0) | 0 (0) | ||
| No | 40 (100) | 41 (100) | ||
Values are represented as mean ± standard deviation or number (%).
BMI = body mass index; PM = partial mastectomy; ALND = axillary lymph node dissection; MRM = modified radical mastectomy; TM = total mastectomy; ER = estrogen receptor; PR = progesterone receptor; HER = human epidermal growth factor receptor.
*Chi-square test or Fisher’s exact test, except †Student’s t-test; ‡One patient in the control group who was not followed up after drain removal within postoperative 30 days was not included (n = 40).
Clinical results of the Ligasure and control groups
| Variables | Control (n = 41) | Ligasure (n = 41) | ||
|---|---|---|---|---|
| Total operation time (min) | 106.71 ± 32.66 | 120.59 ± 43.17 | 0.11 | |
| Hospital stay (day) | 5.37 ± 3.86 | 5.29 ± 4.03 | 0.93 | |
| Duration of drainage (day) | 17.05 ± 5.96 | 13.85 ± 4.45 | 0.01 | |
| Total postoperative drainage volume (mL) | 1,167.74 ± 834.95 | 756.26 ± 499.89 | 0.01 | |
| Actual postoperative drainage volume (mL)‡ | 1,362.85 ± 966.29 | 897.73 ± 531.77 | 0.01 | |
| Drainage volume at hospitalization (mL) | 535.87 ± 502.16 | 481.58 ± 450.72 | 0.61 | |
| Total aspiration volume (mL)‡ | 35.58 ± 139.81 | 13.29 ± 58.88 | 0.36 | |
| Seroma aspiration frequency‡ | > 0.99† | |||
| 0 | 35 (87.5) | 36 (87.8) | ||
| 1–5 | 4 (10.0) | 5 (12.2) | ||
| > 5 | 1 (2.5) | 0 (0) | ||
| Retrieved lymph nodes | 12 (2–31) | 13 (3–27) | 0.45† | |
| Metastatic lymph nodes | 1 (0–23) | 2 (0–24) | 0.54† | |
| Complications‡ | 0.05† | |||
| Yes | 11 (27.5) | 4 (9.8) | ||
| No | 29 (72.5) | 37 (90.2) | ||
Values are represented as mean ± standard deviation or number (%).
*Student’s t-test, except for †Fisher’s exact test; ‡One patient in the control group who did not attend follow-up after drain removal within 30 postoperative days was not included (n = 40).
Figure 2Forest plot of clinical outcomes between the LigaSure and control groups.
SD = standard deviation; CI = confidence interval.
*One patient in the control group who did not attend follow-up after drain removal within 30 postoperative days was excluded (n = 40).
Figure 3The curves of cumulative drainage removal in the LigaSure and control groups.
Figure 4Forest plot of multivariate analyses for associated factors in drainage removal by logistic regression analysis.
HR = hazard ratio; CI = confidence interval; HER = human epidermal growth factor receptor; PM = partial mastectomy; ALND = axillary lymph node dissection; MRM = modified radical mastectomy; TM = total mastectomy.